ECOG-ACRIN research at ASCO 2024
McCormick Place Convention Center, Chicago, IL
Late-breaking data and AI in prostate cancer; long-term results with less radiation in head and neck cancer; optimal chemotherapy for Black women with breast cancer; and results from the first randomized national trial in older adults with pancreas cancer
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present a range of research findings at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and online from May 31 to June 4, 2024. The National Cancer Institute, part of the National Institutes of Health, funded these studies.
Abstract titles are now available. Below are five highlights among the 14 abstracts to be presented by researchers affiliated with ECOG-ACRIN.
Prostate Cancer - Late-breaking abstract submission
- Cabazitaxel with Abiraterone versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 Trial (EA8153). Abstract LBA5000. Background here.
Breast Cancer - Late-breaking abstract submission - a prospective trial that enrolled only Black women
- ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Variants and Taxane Type in Association with Taxane-Induced Peripheral Neuropathy (TIPN) in Black Women with Early-Stage Breast Cancer. Abstract LBA 503. Background here.
Pancreas Cancer – First randomized, prospective national trial of its kind; represents a new approach to geriatric assessment, which can be used in other trials
- A Randomized Phase 2 Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naive Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186. Abstract 4003. Background here.
Head and Neck Cancer – Follow-up on a practice-changing approach using less radiation
- Long-Term Follow-Up of E3311, A Phase 2 Trial of Transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer. Abstract 6009. Primary publication: Ferris RL. J Clin Oncol. 2021.
Prostate Cancer – Evaluation of the use of AI for prognosis
- Prognostic Validation of a Digital Pathology-Based Multi-Modal Artificial Intelligence (MMAI) Biomarker in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the CHAARTED Trial. Abstract 5077.
Interviews
ASCO will release the majority of abstracts on Thursday, May 23, at 5:00 PM (ET). Abstracts are under the ASCO news embargo until then. Please follow the ASCO 2024 Annual Meeting Media Policies. To request an interview under embargo with the authors of any of the abstracts above, email Diane Dragaud, Director of Communications, or call 215-789-3631.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is an expansive membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1400 member institutions and 21,000 research professionals in the United States and around the world. ECOG-ACRIN is known for advancing precision medicine and biomarker research through its leadership of major national clinical trials integrating cutting-edge genomic approaches. Member researchers and advocates collaborate across more than 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute, part of the National Institutes of Health. Follow us on Twitter/ X @eaonc, Facebook, LinkedIn, and Instagram, or call 215.789.3631.
###